Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on REGN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Regeneron could be a solid choice for investors.
Current Quarter Estimates for REGN
In the past 30 days, seven estimates have gone higher for Regeneron while two have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from $3.39 cents a share 30 days ago, to $3.86 today, a move of 13.9%.
Current Year Estimates for REGN
Meanwhile, Regeneron’s current year figures are also looking quite promising, with 12 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $12.85 per share 30 days ago to $14.99 per share today, an increase of 15.9%.
The stock has also started to move higher lately, adding 6.4% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>